Serum free light chain kinetics is predictive of renal response in myeloma patients with renal impairment – an ALLG trial of carfilzomib-dexamethasone therapy in frontline and relapse.

Renal impairment (RI) confers adverse prognosis in myeloma; its reversal and avoidance of dialysis are crucial. We investigated whether serum free light chain (SFLC) measurements can predict renal outcome, to enable change in therapy to optimise prognosis and avoid dialysis.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research